Task: Answer Verification
Input (English): Question: Are genetic polymorphisms of FcγRIIa and FcγRIIIa predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer?
Answer: The FcγRIIa and FcγRIIIa polymorphisms may not be useful molecular biomarkers for the activity of cetuximab in patients with mCRC.
Output (English): no